Vaccine hesitancy in people with multiple sclerosis

Lechner‐Scott, Jeannette; Davis, Joshua S.; Hawkes, Christopher H.; Giovannoni, Gavin; Levy, Michaël; Yeh, Ann Ming

doi:10.1016/j.msard.2022.104102

Multiple Sclerosis and Related Disorders

2022

DOI: 10.1016/j.msard.2022.104102

|View full text |Cite

Vaccine hesitancy in people with multiple sclerosis

Jeannette Lechner‐Scott

Joshua S. Davis²,

Christopher H. Hawkes³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 16 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the immunosuppressive or immunomodulatory activity of disease-modifying treatments (DMTs) affect the immune response to the vaccine [5,6]. Given this, there is a degree of hesitancy among MS patients to be vaccinated against COVID-19 [7][8][9].…”

mentioning

confidence: 99%

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Stastna,

Elberling,

Pontieri

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeWe evaluated whether there was a difference in the occurrence of relapses pre‐ and post‐COVID‐19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis.MethodsWe conducted a population‐based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors.ResultsWe identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID‐19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre‐ and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058–0.070) with the ARR 90 (0.057, 95% CI = 0.047–0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048–0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse.ConclusionsWe did not find evidence of increased relapse activity following the administration of the first dose of the COVID‐19 vaccine.

show abstract

mentioning

confidence: 99%

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Stastna,

Elberling,

Pontieri

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Impfstrategien bei Menschen mit MS

Salmen,

Gold

2024

InFo Neurol Psych

View full text Add to dashboard Cite

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis

Ning,

Cao,

Wang

et al. 2024

Heliyon

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Vaccine hesitancy in people with multiple sclerosis

Cited by 3 publications

References 16 publications

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Impfstrategien bei Menschen mit MS

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis

Contact Info

Product

Resources

About